Exploring co-mutations in CML and ph(+) b-ALL with ABL1 variants: Correlations with survival and treatment response.
Kaitlyn C. Dykes(University of California San Diego), Tiffany Tanaka(UC San Diego Health System), James K. Mangan(UC San Diego Health System), Nicholas J. Protopsaltis(University of California San Diego), Wei Song(Dalian Medical University), Ah‐Reum Jeong(University of California San Diego), Richard Wong(University of California San Diego), Dimitrios Tzachanis(Dana-Farber Cancer Institute), Caitlin Costello(University of California San Diego), Ayad Hamdan(University of California San Diego), Divya Koura(University of California San Diego)
Cited by 0
Related Papers
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|595
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|282
Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells
|Nature Immunology|2001|277
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia
|Journal of Clinical Oncology|2019|274
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults
|New England Journal of Medicine|2024|213